Interestingly, subanalysis of results from phase II trials in melanoma[17,18] have hinted at a greater efficacy of MEK1/2 inhibition in BRAF-mutant patients albeit in small patient numbers (15 and 67 BRAF mutant patients). This evidence concerns the gene MAP2K1 and melanoma.